A lawsuit has been filed against pharmaceutical firm Pfizer, alleging that the company attempted to suppress negative research about its epilepsy drug, Neurontin.
Documents submitted by the plaintiffs allege that the drug company delayed publication of certain studies regarding the medication’s success for conditions other than epilepsy.
They also claim that Pfizer used spin techniques to make results seem more positive and combined both favorable and negative findings together, which distorted research.
The pharmaceutical giant has denied it is at fault, releasing a statement saying it is "committed to the communication of medically or scientifically significant results of all studies, regardless of outcome."
According to the New York Times, some of the studies in question raised doubts about how effectively Neurontin was at treating bipolar disorder, some types of pain and migraines.
In 2004, the drug company paid hundreds of millions of dollars to settle a lawsuit claiming Neurontin was promoted to treat unapproved conditions by Warner-Lambert, a firm which was purchased by Pfizer in 2000.
Pfizer stopped marketing Neurontin in 2004, when it lost its patent protection. The company’s 2007 revenue was $48.4 billion.